GSK’s Shingrix Receives the US FDA’s Approval to Prevent Shingles in Immunocompromised Adults

 GSK’s Shingrix Receives the US FDA’s Approval to Prevent Shingles in Immunocompromised Adults

Shots:

  • The approval is based on studies evaluating the safety & efficacy of Shingrix in adults aged ≥18yrs. who had undergone auHSCT and those undergoing treatment for hematological malignancies (post-hoc analysis)
  • The safety & immunogenicity data were generated in adults who were or anticipated to be, immunodeficient/immunosuppressed due to known therapy including patients with HIV, solid tumors, and renal transplants
  • Shingrix (IM, 2 doses) is a non-live, recombinant sub-unit adjuvanted vaccine, initially approved for the prevention of shingles in adults aged ≥50yrs. in the US. The approval for this new population expands the number of people who can be protected against shingles

Click here ­to­ read full press release/ article | Ref: GSK | Image: Bloomberg Quint

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post